DK2814963T3 - Nukleinsyre omfattende eller kodende for en histonhårnåleløkke og en poly(a)-sekvens eller et polyadenyleringssignal for at øge ekspression af et indkodet terapeutisk protein - Google Patents
Nukleinsyre omfattende eller kodende for en histonhårnåleløkke og en poly(a)-sekvens eller et polyadenyleringssignal for at øge ekspression af et indkodet terapeutisk protein Download PDFInfo
- Publication number
- DK2814963T3 DK2814963T3 DK13704552.2T DK13704552T DK2814963T3 DK 2814963 T3 DK2814963 T3 DK 2814963T3 DK 13704552 T DK13704552 T DK 13704552T DK 2814963 T3 DK2814963 T3 DK 2814963T3
- Authority
- DK
- Denmark
- Prior art keywords
- histonic
- coding
- poly
- sequence
- nucleic acid
- Prior art date
Links
- 108091034057 RNA (poly(A)) Proteins 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 230000008488 polyadenylation Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/000671 WO2013120497A1 (en) | 2012-02-15 | 2012-02-15 | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
PCT/EP2013/000461 WO2013120629A1 (en) | 2012-02-15 | 2013-02-15 | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2814963T3 true DK2814963T3 (da) | 2020-07-27 |
Family
ID=47720472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13704552.2T DK2814963T3 (da) | 2012-02-15 | 2013-02-15 | Nukleinsyre omfattende eller kodende for en histonhårnåleløkke og en poly(a)-sekvens eller et polyadenyleringssignal for at øge ekspression af et indkodet terapeutisk protein |
Country Status (15)
Country | Link |
---|---|
US (5) | US9447431B2 (da) |
EP (2) | EP2814963B1 (da) |
JP (3) | JP6357111B2 (da) |
KR (1) | KR102072013B1 (da) |
CN (2) | CN104114705B (da) |
AU (1) | AU2013220749B2 (da) |
BR (1) | BR112014019627A2 (da) |
CA (1) | CA2862476C (da) |
DK (1) | DK2814963T3 (da) |
ES (1) | ES2806678T3 (da) |
IN (1) | IN2014DN05670A (da) |
MX (1) | MX359953B (da) |
RU (1) | RU2634391C2 (da) |
SG (2) | SG11201403944RA (da) |
WO (2) | WO2013120497A1 (da) |
Families Citing this family (191)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
WO2012170930A1 (en) | 2011-06-08 | 2012-12-13 | Shire Human Genetic Therapies, Inc | Lipid nanoparticle compositions and methods for mrna delivery |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
CN104321432B (zh) | 2012-03-27 | 2018-08-10 | 库瑞瓦格股份公司 | 包含5′top utr的人工核酸分子 |
MX362981B (es) | 2012-03-27 | 2019-02-28 | Curevac Ag | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. |
JP6298039B2 (ja) | 2012-03-27 | 2018-03-20 | キュアバック アーゲー | 人工核酸分子 |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
JP2015513913A (ja) | 2012-04-02 | 2015-05-18 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 修飾ポリヌクレオチド |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
AU2013271392B2 (en) | 2012-06-08 | 2018-02-15 | Ethris Gmbh | Pulmonary delivery of mRNA to non-lung target cells |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
ES2739913T3 (es) | 2013-02-22 | 2020-02-04 | Curevac Ag | Combinación de vacunación e inhibición de la ruta PD-1 |
CN105209490A (zh) | 2013-03-14 | 2015-12-30 | 夏尔人类遗传性治疗公司 | 用于递送mrna编码的抗体的方法和组合物 |
NZ751462A (en) | 2013-03-14 | 2021-07-30 | Shire Human Genetic Therapies | Cftr mrna compositions and related methods and uses |
EP4332576A3 (en) | 2013-03-15 | 2024-04-24 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CN105473157A (zh) | 2013-08-21 | 2016-04-06 | 库瑞瓦格股份公司 | 组合疫苗 |
CA2915712A1 (en) | 2013-08-21 | 2015-02-26 | Margit SCHNEE | Rabies vaccine |
SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
ES2747762T3 (es) | 2013-08-21 | 2020-03-11 | Curevac Ag | Vacuna contra el virus respiratorio sincitial (RSV) |
CA3184564A1 (en) * | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2 |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
SG10201903381TA (en) | 2013-12-30 | 2019-05-30 | Curevac Ag | Artificial nucleic acid molecules |
EP3090052B1 (en) * | 2013-12-30 | 2018-06-13 | CureVac AG | Artificial nucleic acid molecules |
SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
JP6584414B2 (ja) * | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | 人工核酸分子 |
EP3116535B1 (en) | 2014-03-12 | 2019-08-07 | CureVac AG | Combination of vaccination and ox40 agonists |
CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
EP3135763A4 (en) * | 2014-04-24 | 2017-12-27 | Accurna, Inc. | Method for improving protein expression, and composition for protein expression |
US10837039B2 (en) | 2014-06-10 | 2020-11-17 | Curevac Real Estate Gmbh | Methods and means for enhancing RNA production |
ES2931832T3 (es) | 2014-06-25 | 2023-01-03 | Acuitas Therapeutics Inc | Lípidos y formulaciones de nanopartículas lipídicas novedosos para la entrega de ácidos nucleicos |
WO2016077125A1 (en) | 2014-11-10 | 2016-05-19 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
WO2016089945A1 (en) * | 2014-12-03 | 2016-06-09 | Florida State University Research Foundation, Inc. | Modified fibroblast growth factor 1 (fgf-1) polypeptides with increased binding affinity for heparin and associated methods |
DE202015010000U1 (de) * | 2014-12-12 | 2023-07-03 | CureVac SE | Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression |
KR102580696B1 (ko) * | 2014-12-30 | 2023-09-19 | 큐어백 에스이 | 신규 인공 핵산 분자 |
US10618944B2 (en) | 2015-02-27 | 2020-04-14 | Saint Louis University | Tumor suppressor SALL1 as a therapeutic agent for treating cancer |
EP4353257A3 (en) | 2015-04-13 | 2024-08-07 | CureVac Manufacturing GmbH | Method for producing rna compositions |
CN107567497A (zh) | 2015-04-17 | 2018-01-09 | 库瑞瓦格股份公司 | Rna的冻干 |
EP3326641B1 (en) | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
ES2897823T3 (es) | 2015-04-30 | 2022-03-02 | Curevac Ag | Poli(N)polimerasa inmovilizada |
WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
BR112017017949A2 (pt) | 2015-05-15 | 2018-04-10 | Curevac Ag | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna |
WO2016184576A2 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
SG10201910431RA (en) | 2015-05-20 | 2020-01-30 | Curevac Ag | Dry powder composition comprising long-chain rna |
US11608513B2 (en) | 2015-05-29 | 2023-03-21 | CureVac SE | Method for adding cap structures to RNA using immobilized enzymes |
CN113897350A (zh) | 2015-05-29 | 2022-01-07 | 库瑞瓦格房地产有限公司 | 包括至少一个切向流过滤步骤的产生和纯化rna的方法 |
LT3313829T (lt) | 2015-06-29 | 2024-08-12 | Acuitas Therapeutics Inc. | Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui |
US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
EP3350333B1 (en) | 2015-09-17 | 2021-10-27 | ModernaTX, Inc. | Polynucleotides containing a stabilizing tail region |
JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
US11225682B2 (en) | 2015-10-12 | 2022-01-18 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
US20190218546A1 (en) | 2015-10-16 | 2019-07-18 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
US20190225644A1 (en) | 2015-10-16 | 2019-07-25 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
EP3364983A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST RESPIRATORY VIRUS |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
PL3368507T3 (pl) | 2015-10-28 | 2023-03-27 | Acuitas Therapeutics Inc. | Nowe preparaty lipidów i nanocząstek lipidowych do dostarczania kwasów nukleinowych |
US11413346B2 (en) | 2015-11-09 | 2022-08-16 | Curevac Ag | Rotavirus vaccines |
WO2017112865A1 (en) | 2015-12-22 | 2017-06-29 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
WO2017109134A1 (en) | 2015-12-22 | 2017-06-29 | Curevac Ag | Method for producing rna molecule compositions |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
SG11201806340YA (en) | 2016-02-17 | 2018-09-27 | Curevac Ag | Zika virus vaccine |
EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
KR102369898B1 (ko) | 2016-04-08 | 2022-03-03 | 트랜슬레이트 바이오 인코포레이티드 | 다량체 코딩 핵산 및 그 용도 |
US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
EP3458590B9 (en) | 2016-05-18 | 2021-08-18 | ModernaTX, Inc. | Polynucleotides encoding -galactosidase a for the treatment of fabry disease |
BR112018075479A2 (pt) | 2016-06-09 | 2019-03-19 | Curevac Ag | portadores híbridos para carga de ácido nucleico |
EP3469074B1 (en) | 2016-06-13 | 2020-12-09 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
CN105920585B (zh) * | 2016-06-13 | 2019-07-09 | 浙江生创精准医疗科技有限公司 | Mcp-1单独或与其他细胞因子联合在治疗肝纤维化中的用途 |
CA3027201A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
AU2017281374A1 (en) * | 2016-06-22 | 2019-01-03 | City Of Hope | Treatment of canavan disease |
EP3512537B1 (en) * | 2016-09-15 | 2023-11-01 | Elicera Therapeutics AB | T-cell immunotherapy |
JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US20200024347A1 (en) | 2016-11-10 | 2020-01-23 | Iomx Therapeutics Ag | Or10h1 antigen binding proteins and uses thereof |
US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
WO2018107088A2 (en) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
EP3551230A1 (en) | 2016-12-08 | 2019-10-16 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
US11253605B2 (en) | 2017-02-27 | 2022-02-22 | Translate Bio, Inc. | Codon-optimized CFTR MRNA |
CN110337305A (zh) | 2017-02-28 | 2019-10-15 | 赛诺菲 | 治疗性rna |
WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
JP2020513824A (ja) * | 2017-03-24 | 2020-05-21 | キュアバック アーゲー | Crispr関連タンパク質をコードする核酸、及びその使用 |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
CN116693411A (zh) | 2017-04-28 | 2023-09-05 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
CN107245510B (zh) * | 2017-05-23 | 2020-10-30 | 中山大学附属第三医院 | 用于示踪免疫细胞的试剂盒及方法 |
US20210198200A1 (en) | 2017-06-14 | 2021-07-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
KR20200024905A (ko) | 2017-07-04 | 2020-03-09 | 큐어백 아게 | 신규 핵산 분자 |
AU2018298039B2 (en) * | 2017-07-06 | 2023-02-02 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
EP3437650A1 (en) * | 2017-07-31 | 2019-02-06 | Accanis Biotech F&E GmbH & Co KG | Treatment of local skin hypotrophy conditions |
US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
CA3073018A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036638A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR PREPARING MODIFIED RNA |
US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
CN107590533B (zh) * | 2017-08-29 | 2020-07-31 | 中国科学院计算技术研究所 | 一种用于深度神经网络的压缩装置 |
JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
JP2021502079A (ja) | 2017-11-08 | 2021-01-28 | キュアバック アーゲー | RNA配列の適合(Adaptation) |
WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
CA3084061A1 (en) | 2017-12-20 | 2019-06-27 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
US11525158B2 (en) | 2017-12-21 | 2022-12-13 | CureVac SE | Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA |
EP3508499A1 (en) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof |
JP7410135B2 (ja) | 2018-09-19 | 2024-01-09 | モデルナティエックス インコーポレイテッド | 治療薬の細胞内送達のための化合物及び組成物 |
CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
CN113646432A (zh) | 2019-01-23 | 2021-11-12 | 雷杰纳荣制药公司 | 用血管生成素样7(angptl7)抑制剂治疗眼科疾病 |
US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
BR112021014909A2 (pt) | 2019-01-31 | 2021-11-23 | Modernatx Inc | Agitadores tipo vórtex e métodos associados, sistemas e aparelhos destes |
CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
CA3140917A1 (en) * | 2019-05-24 | 2020-12-03 | Empirico Inc. | Treatment of angiopoietin like 7 (angptl7) related diseases |
EP3994171A1 (en) | 2019-07-05 | 2022-05-11 | iOmx Therapeutics AG | Antibodies binding igc2 of igsf11 (vsig3) and uses thereof |
CN112646009B (zh) * | 2019-08-27 | 2022-02-08 | 上海交通大学 | 灵芝免疫调节蛋白突变体及应用 |
CN110548132B (zh) * | 2019-10-24 | 2023-04-25 | 安徽医科大学附属巢湖医院 | TGF-β1蛋白在制备治疗抑郁症的药物中的应用 |
EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
US20240277830A1 (en) | 2020-02-04 | 2024-08-22 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
CN116096375A (zh) * | 2020-02-10 | 2023-05-09 | 犹他大学研究基金会 | 用于诊断、治疗和监测嗜酸性粒细胞介导的炎性疾病的高分子量肝素组合物和方法 |
WO2021191865A1 (en) * | 2020-03-26 | 2021-09-30 | Dusa Pharmaceuticals, Inc. | Management of dermal neurofibromatosis lesions |
TW202204622A (zh) | 2020-04-09 | 2022-02-01 | 大陸商蘇州艾博生物科技有限公司 | 針對冠狀病毒之核酸疫苗 |
CN117003658A (zh) | 2020-04-09 | 2023-11-07 | 苏州艾博生物科技有限公司 | 脂质纳米颗粒组合物 |
JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
CA3182445A1 (en) | 2020-06-11 | 2021-12-16 | Francisco Leon | Methods and compositions for preventing type 1 diabetes |
JP2023532707A (ja) | 2020-06-30 | 2023-07-31 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
US20240010720A1 (en) | 2020-07-06 | 2024-01-11 | Iomx Therapeutics Ag | Antibodies binding igv of igsf11 (vsig3) and uses thereof |
WO2022016070A1 (en) | 2020-07-16 | 2022-01-20 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
BR112023000537A2 (pt) | 2020-07-31 | 2023-01-31 | Chugai Pharmaceutical Co Ltd | Composições farmacêuticas incluindo célula que expressa o receptor quimérico |
CN114391008B (zh) | 2020-08-20 | 2024-05-03 | 苏州艾博生物科技有限公司 | 脂质化合物和脂质纳米颗粒组合物 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN112175988B (zh) * | 2020-09-15 | 2021-06-15 | 广东省农业科学院蔬菜研究所 | 黄瓜韧皮部凝集素CsPL1在抗瓜类疫病中的应用 |
CN116635425A (zh) | 2020-11-03 | 2023-08-22 | 德国癌症研究中心公共法律基金会 | 靶细胞限制性、共刺激性、双特异性二价抗cd28抗体 |
AU2021405281A1 (en) | 2020-12-22 | 2023-07-06 | CureVac SE | Rna vaccine against sars-cov-2 variants |
CN112516288B (zh) * | 2020-12-22 | 2023-04-18 | 西藏阿那达生物医药科技有限责任公司 | N-糖基化修饰之灵芝免疫调节蛋白的应用 |
WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022152141A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Polymer conjugated lipid compounds and lipid nanoparticle compositions |
AU2022226164A1 (en) | 2021-02-26 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
US20240174768A1 (en) | 2021-03-03 | 2024-05-30 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Bispecific antibodies enhancing cell mediated immune responses |
WO2022241130A1 (en) | 2021-05-12 | 2022-11-17 | NexEos Diagnostics, Inc. | Methods of manufacturing a high molecular weight heparin compound |
JP2024517529A (ja) | 2021-05-24 | 2024-04-23 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
TW202317627A (zh) | 2021-06-25 | 2023-05-01 | 日商中外製藥股份有限公司 | 抗ctla-4抗體 |
IL308633A (en) | 2021-06-25 | 2024-01-01 | Chugai Pharmaceutical Co Ltd | Use of anti-CTLA-4 antibodies |
CN113425855B (zh) * | 2021-06-28 | 2023-11-07 | 深圳瑞吉生物科技有限公司 | 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用 |
TW202328067A (zh) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | 環狀脂質及其使用方法 |
CA3231523A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
AR127312A1 (es) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
WO2023056917A1 (en) | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
CN116064598B (zh) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
CN113813369B (zh) * | 2021-11-09 | 2023-09-22 | 浙江省农业科学院 | 用于预防/治疗仔猪肠道损伤的egf/mmt复合物 |
CN113980987A (zh) * | 2021-12-06 | 2022-01-28 | 上海市农业科学院 | 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用 |
AU2022422983A1 (en) | 2021-12-23 | 2024-05-16 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compound and lipid nanoparticle composition |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
CN114711192B (zh) * | 2022-04-13 | 2022-11-29 | 中国科学院西北高原生物研究所 | 一种长效抑郁症动物模型的构建试剂盒及构建方法 |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
WO2024118866A1 (en) | 2022-12-01 | 2024-06-06 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
WO2024133940A2 (en) | 2022-12-23 | 2024-06-27 | Iomx Therapeutics Ag | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5908779A (en) | 1993-12-01 | 1999-06-01 | University Of Connecticut | Targeted RNA degradation using nuclear antisense RNA |
WO1998042856A1 (en) | 1997-03-21 | 1998-10-01 | Enzo Therapeutics, Inc., A Fully Owned Subsidiary Of Enzo Biochem, Inc. | Vectors and viral vectors, and packaging cell lines for propagating same |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
EP2305699B1 (de) | 2001-06-05 | 2014-08-13 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose |
US8021875B2 (en) | 2001-08-27 | 2011-09-20 | Roche Madison Inc. | Methods for expression of transgenes |
AU2002350039A1 (en) | 2001-10-29 | 2003-05-12 | Renovis, Inc. | Method for isolating cell-type specific mrnas |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
EP2500437B1 (en) | 2003-01-21 | 2016-11-30 | PTC Therapeutics, Inc. | Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
DK1685251T3 (da) | 2003-10-10 | 2014-03-24 | Powderject Vaccines Inc | Nukleinsyrekonstruktioner |
CN1863913B (zh) | 2003-10-24 | 2011-01-12 | 思兰克斯有限公司 | 通过mar序列的多次转染过程在哺乳动物细胞中实现高效基因转移和表达 |
DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
EP2578685B1 (en) | 2005-08-23 | 2019-04-17 | The Trustees Of The University Of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
AU2007280690C1 (en) | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
ES2537703T3 (es) | 2008-01-31 | 2015-06-11 | Curevac Gmbh | Ácidos nucleicos que comprenden la fórmula (NuGlXmGnNv)a y sus derivados como agentes/adyuvantes inmunoestimuladores |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
EP2429585B1 (en) | 2009-05-15 | 2018-04-18 | IRX Therapeutics, Inc. | Vaccine immunotherapy |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
AU2011285200B2 (en) | 2010-07-30 | 2014-08-21 | CureVac SE | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
WO2012019630A1 (en) * | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120499A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120497A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
CN104321432B (zh) | 2012-03-27 | 2018-08-10 | 库瑞瓦格股份公司 | 包含5′top utr的人工核酸分子 |
JP6298039B2 (ja) | 2012-03-27 | 2018-03-20 | キュアバック アーゲー | 人工核酸分子 |
MX362981B (es) | 2012-03-27 | 2019-02-28 | Curevac Ag | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. |
EP3498267A1 (en) | 2012-05-25 | 2019-06-19 | CureVac AG | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
ES2739913T3 (es) | 2013-02-22 | 2020-02-04 | Curevac Ag | Combinación de vacunación e inhibición de la ruta PD-1 |
ES2759910T3 (es) | 2013-08-21 | 2020-05-12 | Curevac Ag | Composición y vacuna para el tratamiento del cáncer de pulmón |
CN105473157A (zh) | 2013-08-21 | 2016-04-06 | 库瑞瓦格股份公司 | 组合疫苗 |
CA2915712A1 (en) | 2013-08-21 | 2015-02-26 | Margit SCHNEE | Rabies vaccine |
SG10201801433XA (en) | 2013-08-21 | 2018-04-27 | Curevac Ag | Composition and vaccine for treating prostate cancer |
ES2747762T3 (es) | 2013-08-21 | 2020-03-11 | Curevac Ag | Vacuna contra el virus respiratorio sincitial (RSV) |
SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
SG10201903381TA (en) | 2013-12-30 | 2019-05-30 | Curevac Ag | Artificial nucleic acid molecules |
JP6584414B2 (ja) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | 人工核酸分子 |
EP3116535B1 (en) | 2014-03-12 | 2019-08-07 | CureVac AG | Combination of vaccination and ox40 agonists |
CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
US10837039B2 (en) | 2014-06-10 | 2020-11-17 | Curevac Real Estate Gmbh | Methods and means for enhancing RNA production |
DE202015010000U1 (de) | 2014-12-12 | 2023-07-03 | CureVac SE | Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression |
US20170326225A1 (en) | 2014-12-16 | 2017-11-16 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
KR102580696B1 (ko) | 2014-12-30 | 2023-09-19 | 큐어백 에스이 | 신규 인공 핵산 분자 |
EP4353257A3 (en) | 2015-04-13 | 2024-08-07 | CureVac Manufacturing GmbH | Method for producing rna compositions |
CN107567497A (zh) | 2015-04-17 | 2018-01-09 | 库瑞瓦格股份公司 | Rna的冻干 |
EP3326641B1 (en) | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
WO2016174227A1 (en) | 2015-04-30 | 2016-11-03 | Curevac Ag | Method for in vitro transcription using an immobilized restriction enzyme |
ES2897823T3 (es) | 2015-04-30 | 2022-03-02 | Curevac Ag | Poli(N)polimerasa inmovilizada |
WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
BR112017017949A2 (pt) | 2015-05-15 | 2018-04-10 | Curevac Ag | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna |
WO2016184576A2 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
SG10201910431RA (en) | 2015-05-20 | 2020-01-30 | Curevac Ag | Dry powder composition comprising long-chain rna |
CN113897350A (zh) | 2015-05-29 | 2022-01-07 | 库瑞瓦格房地产有限公司 | 包括至少一个切向流过滤步骤的产生和纯化rna的方法 |
US11608513B2 (en) | 2015-05-29 | 2023-03-21 | CureVac SE | Method for adding cap structures to RNA using immobilized enzymes |
EP3310384A1 (en) | 2015-06-17 | 2018-04-25 | CureVac AG | Vaccine composition |
EP4239080A3 (en) | 2015-07-01 | 2023-11-01 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
EP3331555A1 (en) | 2015-08-05 | 2018-06-13 | CureVac AG | Epidermal mrna vaccine |
WO2017025120A1 (en) | 2015-08-07 | 2017-02-16 | Curevac Ag | Process for the in vivo production of rna in a host cell |
ES2837100T3 (es) | 2015-08-10 | 2021-06-29 | Curevac Real Estate Gmbh | Método de aumento de la replicación de una molécula de ADN circular |
WO2017036580A1 (en) | 2015-08-28 | 2017-03-09 | Curevac Ag | Artificial nucleic acid molecules |
-
2012
- 2012-02-15 WO PCT/EP2012/000671 patent/WO2013120497A1/en active Application Filing
-
2013
- 2013-02-15 AU AU2013220749A patent/AU2013220749B2/en active Active
- 2013-02-15 EP EP13704552.2A patent/EP2814963B1/en active Active
- 2013-02-15 IN IN5670DEN2014 patent/IN2014DN05670A/en unknown
- 2013-02-15 CN CN201380009418.2A patent/CN104114705B/zh active Active
- 2013-02-15 KR KR1020147025605A patent/KR102072013B1/ko active IP Right Grant
- 2013-02-15 EP EP20171676.8A patent/EP3741859A1/en active Pending
- 2013-02-15 DK DK13704552.2T patent/DK2814963T3/da active
- 2013-02-15 CN CN201810369974.5A patent/CN108570468B/zh active Active
- 2013-02-15 SG SG11201403944RA patent/SG11201403944RA/en unknown
- 2013-02-15 SG SG10201606784QA patent/SG10201606784QA/en unknown
- 2013-02-15 MX MX2014009884A patent/MX359953B/es active IP Right Grant
- 2013-02-15 US US14/378,606 patent/US9447431B2/en active Active
- 2013-02-15 JP JP2014556959A patent/JP6357111B2/ja active Active
- 2013-02-15 BR BR112014019627A patent/BR112014019627A2/pt not_active Application Discontinuation
- 2013-02-15 CA CA2862476A patent/CA2862476C/en active Active
- 2013-02-15 RU RU2014137109A patent/RU2634391C2/ru active
- 2013-02-15 WO PCT/EP2013/000461 patent/WO2013120629A1/en active Application Filing
- 2013-02-15 ES ES13704552T patent/ES2806678T3/es active Active
-
2016
- 2016-08-10 US US15/233,933 patent/US10111968B2/en active Active
-
2018
- 2018-02-19 US US15/899,326 patent/US10610605B2/en active Active
- 2018-02-19 US US15/899,336 patent/US10898589B2/en active Active
- 2018-02-27 JP JP2018032670A patent/JP6720235B2/ja active Active
-
2020
- 2020-06-17 JP JP2020104281A patent/JP6922038B2/ja active Active
- 2020-09-14 US US17/020,517 patent/US20210060181A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2814963T3 (da) | Nukleinsyre omfattende eller kodende for en histonhårnåleløkke og en poly(a)-sekvens eller et polyadenyleringssignal for at øge ekspression af et indkodet terapeutisk protein | |
CY2020020I2 (el) | Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων | |
DK2945647T3 (da) | Immunogene wt-1-peptider og anvendelsesmetoder deraf | |
DK2892330T3 (da) | Genetisk modificeret mus og fremgangsmåder til anvendelse deraf | |
DK2603590T3 (da) | Nukleinsyre omfattende eller kodende for et histon stem-loop og en poly(a) se-kvens eller et polyadenyleringssignal til forøgelse af ekspressionen af et kodet protein | |
DK2900657T3 (da) | Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse | |
CL2015001321A1 (es) | Anticuerpos anti-ceacam5 y usos de éstos | |
DK3744835T3 (da) | Dna modificerende fusionsproteiner og metoder til anvendelse deraf | |
DK2931891T3 (da) | Rna-styret modificering af menneskelige genomer | |
BR112014031828A2 (pt) | preparação, usos e formas sólidas de ácido obeticólico | |
DK2931143T3 (da) | Implantat og føring til kæbe-ansigts-kirurgi | |
DK2852680T3 (da) | Fremgangsmåder og processer til ikke-invasiv evaluering af genetiske variationer | |
ES2660615T8 (es) | Vectores de CMVH y CMVRh recombinantes y usos de los mismos | |
DK3418300T3 (da) | Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf | |
BR112012016793A2 (pt) | compostos tipo fumagilol e métodos de fazer e usar os mesmos | |
DK2611316T3 (da) | Skridsikker sok og fremgangsmåde til at fremstille den | |
DK2892912T3 (da) | C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf | |
DK2806892T3 (da) | Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser | |
DK2974732T3 (da) | Olie-ekstraheret produkt af indigo naturalis og fremgangsmåde til fremstilling og anvendelse deraf | |
BR112014023577A2 (pt) | Métodos e dispositivos de codificação e de decodificação de sinais | |
BR302012006546S1 (pt) | Configuracao aplicada em instrumento medico | |
DK3232663T3 (da) | Fremgangsmåder og anordninger til afkodning | |
BR112013017488A2 (pt) | peptídeos imunogênicos multiméricos e monoméricos | |
DK2782598T3 (da) | Rekombinante proteiner og terapeutiske anvendelser deraf | |
DK2931313T3 (da) | Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer |